- Home
- HMY vs BBIO Comparison
HMY vs BBIO Comparison
Compare HMY & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMY
- BBIO
- Stock Information
- Founded
- HMY 1950
- BBIO 2015
- Country
- HMY South Africa
- BBIO United States
- Employees
- HMY N/A
- BBIO 730
- Industry
- HMY Precious Metals
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- HMY Basic Materials
- BBIO Health Care
- Exchange
- HMY Nasdaq
- BBIO Nasdaq
- Market Cap
- HMY 7.5B
- BBIO 6.7B
- IPO Year
- HMY N/A
- BBIO 2019
- Fundamental
- Price
- HMY $14.07
- BBIO $35.11
- Analyst Decision
- HMY Sell
- BBIO Strong Buy
- Analyst Count
- HMY 3
- BBIO 11
- Target Price
- HMY $6.60
- BBIO $52.90
- AVG Volume (30 Days)
- HMY 6.8M
- BBIO 2.8M
- Earning Date
- HMY 01-01-0001
- BBIO 05-01-2025
- Dividend Yield
- HMY 1.08%
- BBIO N/A
- EPS Growth
- HMY 16.30
- BBIO N/A
- EPS
- HMY 0.88
- BBIO N/A
- Revenue
- HMY $3,553,951,394.00
- BBIO $221,902,000.00
- Revenue This Year
- HMY $17.62
- BBIO $6.31
- Revenue Next Year
- HMY $7.93
- BBIO $131.17
- P/E Ratio
- HMY $15.52
- BBIO N/A
- Revenue Growth
- HMY 16.84
- BBIO 2285.27
- 52 Week Low
- HMY $7.97
- BBIO $21.62
- 52 Week High
- HMY $14.38
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- HMY 75.58
- BBIO 53.76
- Support Level
- HMY $12.50
- BBIO $35.77
- Resistance Level
- HMY $13.12
- BBIO $37.06
- Average True Range (ATR)
- HMY 0.40
- BBIO 1.39
- MACD
- HMY 0.12
- BBIO 0.30
- Stochastic Oscillator
- HMY 88.38
- BBIO 57.12
About HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.